About the study
This Phase 3 study is evaluating lunsekimig, an investigational biologic, compared with placebo in adults with inadequately controlled COPD whose disease is characterized by an eosinophilic phenotype — a subtype linked to higher blood eosinophil counts. Participants attend study visits at our Madison Heights office over approximately one year.
Who can participate
You may be eligible if you:
- Are between 40 and 80 years old
- Have a diagnosis of COPD that remains inadequately controlled on current therapy
- Have bloodwork suggesting an eosinophilic phenotype
- Are willing to attend on-site visits over 52 weeks
A research coordinator will confirm eligibility at a screening visit.
What to expect
- An initial screening visit including spirometry, bloodwork, and eligibility review
- Regular follow-up visits with breathing tests and study drug administration
- Compensation for time and travel at each visit